Kritika Mehrotra, Consultant Medical Oncologist at Hinduja Hospital, shared on LinkedIn:
“Delighted to share that our abstract has been accepted for poster presentation at ESMO Congress 2026 in Madrid, where I will be presenting on 24 October.
‘Phenotype-guided rapid drug desensitization in oncology: safety and treatment outcomes from a real-world multiagent cohort’
Hypersensitivity reactions can interrupt effective anticancer treatment and complicate decisions about continuing therapy. Our work examines phenotype-guided rapid drug desensitization across multiple anticancer agents, focusing on safety and treatment outcomes in clinical practice.
Grateful to my mentors, co-authors, and the clinical and nursing teams at SunAct Cancer Institute and P. D. Hinduja Hospital, Khar, whose collaboration made this work possible.
Looking forward to sharing our experience, learning from colleagues, and connecting with others interested in drug hypersensitivity, supportive oncology, and treatment continuity.
If you’re attending ESMO, I would love to connect!”
Other articles about ESMO 2026 on OncoDaily.
